TD Cowen analyst Tyler Van Buren has maintained their bullish stance on SYRE stock, giving a Buy rating on February 20.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tyler Van Buren has given his Buy rating due to a combination of factors, primarily the unusually rich catalyst calendar Spyre is facing over the next year. The company is on track to deliver six Phase II readouts across its SKYLINE-UC inflammatory bowel disease program and SKYWAY rheumatology studies, which he expects can substantially re-rate the stock as clinical proof-of-concept is established.
He highlights the differentiated, long-acting antibody portfolio targeting three well-validated mechanisms—α4β7, TL1A, and IL-23p19—with large addressable markets in ulcerative colitis, Crohn’s disease, and related autoimmune conditions. Van Buren assigns multibillion-dollar peak sales potential to SPY001 and SPY002 alone by 2035 and notes KOL feedback suggesting SPY001 could become a preferred option if its clinical profile is confirmed, supporting a favorable risk/reward and justifying the Buy recommendation.
In another report released on February 20, Citi also maintained a Buy rating on the stock with a $64.00 price target.